Screener
LB Pharmaceuticals Inc LBRX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Realized gain on sale of marketable securities, net | — | 119 |
| Gain on change in fair value of derivative instruments | 200 | 768 |
| Total non-operating income | 3,050 | 1,123 |
| Loss before income tax | (19,054) | (5,306) |
| Income tax provision | — | — |
| Net loss | $(19,054) | $(5,306) |
| Net loss per share, basic and diluted | $(0.67) | $(14.79) |
| Weighted average shares outstanding used in calculating net loss per share, basic and diluted | 28,241,701 | 358,777 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's income tax?
- LB Pharmaceuticals Inc (LBRX) reported income tax of $0 in Q1 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about LB Pharmaceuticals Inc's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude